The botanical and chemical basics
Kratom (Mitragyna speciosa)
Kratom is the dried leaf of a tree in the Rubiaceae family — the same plant family as coffee. Its primary psychoactive compounds are alkaloids, principally mitragynine (60–70% of total alkaloid content) and 7-hydroxymitragynine (under 2% in natural leaf). Mitragynine is a partial agonist at mu-opioid receptors and also active at adrenergic and serotonin receptors. See our alkaloid guide for the chemistry.
Cannabis (Cannabis sativa) and THC
Cannabis is a flowering plant in the Cannabaceae family. Its primary psychoactive compound is delta-9-tetrahydrocannabinol (THC), a cannabinoid that binds the body's CB1 and CB2 cannabinoid receptors. THC effects include euphoria, altered perception, increased appetite, and at higher doses anxiety and impaired cognition.
Delta-8 THC
Delta-8 is a chemical isomer of delta-9 THC — the same molecular formula but a different position of one chemical bond. It occurs naturally in cannabis at very low concentrations. Most commercial delta-8 is produced by acid-catalyzed conversion from CBD, which became commercially viable after the 2018 Farm Bill made hemp-derived CBD legal. Delta-8 effects are qualitatively similar to delta-9 but commonly reported as milder.
Hemp-derived delta-9
After 2018, products containing delta-9 THC at concentrations under 0.3% by dry weight became federally legal as hemp products. By using high-volume gummies or edibles, manufacturers fit psychoactive doses of delta-9 into products that technically meet the 0.3% threshold by total weight. This is the regulatory loophole behind much of the "hemp-derived THC" market.
The pharmacology — they are not similar
Side by side at the receptor level:
- Kratom: mu-opioid partial agonist, alpha-2 adrenergic agonist, 5-HT receptor activity, dopamine release at higher doses
- THC (delta-8 or delta-9): CB1 and CB2 cannabinoid receptor partial agonist, with downstream effects on dopamine, glutamate, GABA, and endocannabinoid signaling
Different receptors. Different second-messenger pathways. Different neurological consequences. The user-facing experience can be superficially overlapping at certain doses (relaxation, mood elevation), but the mechanism is entirely different, and that difference matters for: tolerance dynamics, withdrawal profile, drug interactions, contraindications, and appropriate use contexts.
The effects — qualitative differences
Kratom
- Low dose: stimulation, focus, mood elevation
- Higher dose: relaxation, analgesia, sedation
- Dose-dependent shift from stimulant to sedative
- Effect duration: 4–6 hours
- Minimal cognitive impairment at typical doses
THC (delta-9 or delta-8)
- Euphoria, altered perception, time distortion
- Cognitive impairment proportional to dose
- Increased appetite
- Acute anxiety or paranoia possible, especially at higher doses
- Effect duration: 2–4 hours (smoked), 4–8 hours (edibles)
The risk profiles — also different
Kratom risks
- Dependence with daily use — real and meaningful, with withdrawal symptoms on cessation. See our tolerance and dependence guide.
- Cardiovascular load — heart rate and blood pressure increases at stimulant doses
- Drug interactions — particularly with other sedatives, opioids, benzodiazepines, and certain medications metabolized by liver enzymes
- Synthetic 7-OH products — the highest-risk subcategory, banned by KCPA-style laws. See our synthetic 7-OH explainer.
THC risks
- Acute anxiety, paranoia, panic — particularly at high doses or with high-THC flower
- Impaired driving and cognition for hours after use
- Cannabinoid hyperemesis syndrome with chronic heavy use
- Cognitive and motivational impacts with chronic adolescent use (most concerning population)
- Cannabis use disorder in roughly 9% of users (and ~17% of adolescent-onset users), per CDC data
- Acute psychosis risk in vulnerable individuals or with very-high- potency products
Comparison table
(Best understood with the caveats above; this is a quick reference, not a substitute for the detail.)
- Plant family: Kratom — Rubiaceae | THC — Cannabaceae
- Active compound: Kratom — mitragynine + 7-OH | THC — delta-9 or delta-8 THC
- Receptor target: Kratom — mu-opioid, adrenergic | THC — cannabinoid CB1/CB2
- Federal legality (US): Kratom — legal | Delta-9 — Schedule I; hemp-derived delta-9 under 0.3% legal | Delta-8 — gray area
- Tolerance speed: Kratom — fast (1–4 weeks daily) | THC — moderate (weeks to months daily)
- Withdrawal: Kratom — physical, opioid-like | THC — psychological + mild physical
- Cognitive impairment: Kratom — minimal at typical doses | THC — substantial
- Driving safe?: Both — no, neither is safe to drive on
The legal picture in brief
Kratom is federally legal in the United States and regulated state by state — most states permit it; a handful prohibit it. See our legality guide for the current map.
Delta-9 THC from cannabis is federally Schedule I, with state-level medical and recreational programs operating under federal enforcement discretion. Delta-9 from hemp under 0.3% by dry weight is federally legal under the 2018 Farm Bill, but many states have moved to restrict it independently.
Delta-8 is in active legal flux — federally legal under one reading of the Farm Bill, but more than 20 states have specifically restricted or banned it.
The legal frameworks evolved separately and don't reflect a coherent comparative judgment about either substance.
The combination question
Mixing kratom and THC is poorly studied. What's known: the combination produces additive sedation, can amplify cardiovascular effects, and increases cognitive impairment. Practical guidance if you choose to combine them despite these unknowns:
- Very low doses of each, never anywhere near typical recreational doses
- Never while driving or operating equipment
- Never with alcohol added on top
- Not as a regular pattern
- Not in combination with prescription medications without a physician's input
The honest bottom line
Kratom and THC are different plants, different molecules, different receptor systems, different effects, different risks, and different appropriate use cases. They share a retail shelf and a regulatory conversation, not a pharmacology. Treating them as the same general category — "alternative wellness" or "natural psychoactives" — is the kind of mental shortcut that produces bad consumer decisions. Pick one based on what you actually want and what you can responsibly manage; don't substitute one for the other based on a vague sense that they're similar.
Frequently Asked Questions
Are kratom and THC the same thing?
No. They come from different plant species, contain different active compounds, act on entirely different receptor systems, and produce fundamentally different effects. Kratom (Mitragyna speciosa) contains alkaloids like mitragynine that act primarily on opioid and adrenergic receptors. THC (delta-9-tetrahydrocannabinol from Cannabis sativa) acts on cannabinoid receptors. The only thing kratom and THC have in common is that both are botanical compounds with psychoactive properties — beyond that, the comparison ends.
What is delta-8 THC and how is it different from delta-9?
Delta-9 THC is the primary psychoactive compound in cannabis. Delta-8 THC is a chemical isomer — same molecular formula, slightly different arrangement — that occurs naturally in cannabis at very small amounts. Most commercially available delta-8 is produced by chemical conversion from CBD, which exists in a federal legal gray zone exploited by hemp processors after the 2018 Farm Bill. Delta-8 produces effects qualitatively similar to delta-9 but is reported to be milder. The legal status of delta-8 is contested and shifting state by state.
Why are kratom, delta-8, and delta-9 sold in the same shops?
Convenience stores, vape shops, and 'smoke shops' carry whatever is profitable and legally ambiguous, which often means all three plus other compounds (kava, CBD, etc.). The shared retail channel creates a false impression of category equivalence — that these are all 'alternative wellness' products in the same family. They are not. Each has different pharmacology, different legal status, different safety profile, and different appropriate use cases. Lumping them together because they share a shelf is a category error that leads to bad consumer decisions.
Which is safer — kratom or THC?
Neither is straightforwardly 'safer' — they have different risk profiles. THC at recreational doses is generally lower-risk in healthy adults but is associated with anxiety, paranoia, and impaired driving acutely, and with cognitive and motivational concerns at heavy chronic use, particularly in adolescents. Kratom carries a real dependence risk with daily use because of its mu-opioid receptor activity, and adverse events are concentrated in poly-drug use and synthetic 7-OH products. Both have specific contraindications (cardiovascular, pregnancy, drug interactions) that matter more than blanket comparisons.
Can I take kratom and THC together?
Some users do, but the combination is poorly studied, the effects are unpredictable, and the additive sedation can be substantial. Both compounds can independently cause dizziness and impaired coordination at higher doses; combining them compounds the effect. Cardiovascular load, particularly with stimulating doses of kratom plus high-THC products, is a real concern. If you choose to combine them despite these risks, do so at very low doses of each, never while driving or operating equipment, never with alcohol on top, and not as a regular pattern.
Why is kratom legal where THC isn't (or vice versa)?
Because they are regulated under entirely different legal frameworks. Cannabis-derived THC is federally Schedule I (with hemp-derived delta-9 under 0.3% being legal under the 2018 Farm Bill), and state-legal cannabis programs operate in tension with federal law. Kratom is unscheduled at the federal level and regulated state-by-state — most states permit it, a handful prohibit it. The two regulatory regimes evolved independently and don't reflect a coherent comparative judgment about either substance; they reflect different histories of legislative attention.